These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 17321776)

  • 1. Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid.
    Dickson P; McEntee M; Vogler C; Le S; Levy B; Peinovich M; Hanson S; Passage M; Kakkis E
    Mol Genet Metab; 2007 May; 91(1):61-8. PubMed ID: 17321776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I.
    Kakkis E; McEntee M; Vogler C; Le S; Levy B; Belichenko P; Mobley W; Dickson P; Hanson S; Passage M
    Mol Genet Metab; 2004; 83(1-2):163-74. PubMed ID: 15464431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early versus late treatment of spinal cord compression with long-term intrathecal enzyme replacement therapy in canine mucopolysaccharidosis type I.
    Dickson PI; Hanson S; McEntee MF; Vite CH; Vogler CA; Mlikotic A; Chen AH; Ponder KP; Haskins ME; Tippin BL; Le SQ; Passage MB; Guerra C; Dierenfeld A; Jens J; Snella E; Kan SH; Ellinwood NM
    Mol Genet Metab; 2010; 101(2-3):115-22. PubMed ID: 20655780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biodistribution and pharmacodynamics of recombinant human alpha-L-iduronidase (rhIDU) in mucopolysaccharidosis type I-affected cats following multiple intrathecal administrations.
    Vite CH; Wang P; Patel RT; Walton RM; Walkley SU; Sellers RS; Ellinwood NM; Cheng AS; White JT; O'Neill CA; Haskins M
    Mol Genet Metab; 2011 Jul; 103(3):268-74. PubMed ID: 21482164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycosaminoglycan storage in neuroanatomical regions of mucopolysaccharidosis I dogs following intrathecal recombinant human iduronidase.
    Chen A; Vogler C; McEntee M; Hanson S; Ellinwood NM; Jens J; Snella E; Passage M; Le S; Guerra C; Dickson P
    APMIS; 2011 Aug; 119(8):513-21. PubMed ID: 21749451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I.
    Dickson P; Peinovich M; McEntee M; Lester T; Le S; Krieger A; Manuel H; Jabagat C; Passage M; Kakkis ED
    J Clin Invest; 2008 Aug; 118(8):2868-76. PubMed ID: 18654665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intra-articular enzyme replacement therapy with rhIDUA is safe, well-tolerated, and reduces articular GAG storage in the canine model of mucopolysaccharidosis type I.
    Wang RY; Aminian A; McEntee MF; Kan SH; Simonaro CM; Lamanna WC; Lawrence R; Ellinwood NM; Guerra C; Le SQ; Dickson PI; Esko JD
    Mol Genet Metab; 2014 Aug; 112(4):286-93. PubMed ID: 24951454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I.
    Kakkis ED; McEntee MF; Schmidtchen A; Neufeld EF; Ward DA; Gompf RE; Kania S; Bedolla C; Chien SL; Shull RM
    Biochem Mol Med; 1996 Aug; 58(2):156-67. PubMed ID: 8812735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme replacement therapy in feline mucopolysaccharidosis I.
    Kakkis ED; Schuchman E; He X; Wan Q; Kania S; Wiemelt S; Hasson CW; O'Malley T; Weil MA; Aguirre GA; Brown DE; Haskins ME
    Mol Genet Metab; 2001 Mar; 72(3):199-208. PubMed ID: 11243725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcranial pulsed ultrasound facilitates brain uptake of laronidase in enzyme replacement therapy for Mucopolysaccharidosis type I disease.
    Hsu YH; Liu RS; Lin WL; Yuh YS; Lin SP; Wong TT
    Orphanet J Rare Dis; 2017 Jun; 12(1):109. PubMed ID: 28595620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific antibody titer alters the effectiveness of intrathecal enzyme replacement therapy in canine mucopolysaccharidosis I.
    Dickson PI; Ellinwood NM; Brown JR; Witt RG; Le SQ; Passage MB; Vera MU; Crawford BE
    Mol Genet Metab; 2012 May; 106(1):68-72. PubMed ID: 22402327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune response to intrathecal enzyme replacement therapy in mucopolysaccharidosis I patients.
    Vera M; Le S; Kan SH; Garban H; Naylor D; Mlikotic A; Kaitila I; Harmatz P; Chen A; Dickson P
    Pediatr Res; 2013 Dec; 74(6):712-20. PubMed ID: 24002329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Replacing the enzyme alpha-L-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I.
    Dierenfeld AD; McEntee MF; Vogler CA; Vite CH; Chen AH; Passage M; Le S; Shah S; Jens JK; Snella EM; Kline KL; Parkes JD; Ware WA; Moran LE; Fales-Williams AJ; Wengert JA; Whitley RD; Betts DM; Boal AM; Riedesel EA; Gross W; Ellinwood NM; Dickson PI
    Sci Transl Med; 2010 Dec; 2(60):60ra89. PubMed ID: 21123810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous infusion of enzyme replacement therapy is inferior to weekly infusions in MPS I dogs.
    Passage MB; Krieger AW; Peinovich MC; Lester T; Le SQ; Dickson PI; Kakkis ED
    J Inherit Metab Dis; 2009 Dec; 32 Suppl 1(Suppl 1):S253-8. PubMed ID: 19562502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful induction of immune tolerance to enzyme replacement therapy in canine mucopolysaccharidosis I.
    Kakkis E; Lester T; Yang R; Tanaka C; Anand V; Lemontt J; Peinovich M; Passage M
    Proc Natl Acad Sci U S A; 2004 Jan; 101(3):829-34. PubMed ID: 14715900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of laronidase delivered into the spinal canal for treatment of cervical stenosis in mucopolysaccharidosis I.
    Dickson PI; Kaitila I; Harmatz P; Mlikotic A; Chen AH; Victoroff A; Passage MB; Madden J; Le SQ; Naylor DE;
    Mol Genet Metab; 2015; 116(1-2):69-74. PubMed ID: 26260077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrathecal enzyme replacement therapy reverses cognitive decline in mucopolysaccharidosis type I.
    Nestrasil I; Shapiro E; Svatkova A; Dickson P; Chen A; Wakumoto A; Ahmed A; Stehel E; McNeil S; Gravance C; Maher E
    Am J Med Genet A; 2017 Mar; 173(3):780-783. PubMed ID: 28211988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression.
    Munoz-Rojas MV; Vieira T; Costa R; Fagondes S; John A; Jardim LB; Vedolin LM; Raymundo M; Dickson PI; Kakkis E; Giugliani R
    Am J Med Genet A; 2008 Oct; 146A(19):2538-44. PubMed ID: 18792977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ocular lesions in canine mucopolysaccharidosis I and response to enzyme replacement therapy.
    Newkirk KM; Atkins RM; Dickson PI; Rohrbach BW; McEntee MF
    Invest Ophthalmol Vis Sci; 2011 Jul; 52(8):5130-5. PubMed ID: 21436264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone marrow transplantation in canine mucopolysaccharidosis I. Effects within the central nervous system.
    Shull RM; Hastings NE; Selcer RR; Jones JB; Smith JR; Cullen WC; Constantopoulos G
    J Clin Invest; 1987 Feb; 79(2):435-43. PubMed ID: 3100576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.